BioVie Inc. (OTCMKTS:BIVI) Files An 8-K Other Events
On April 3, 2017, BioVie Inc. (the Company) announced, among
other things, that it has received notice from the US Food and
Drug Administration (FDA) that the planned Phase 2a clinical
trial of the Companys new drug candidate BIV201 may be initiated,
and that the Company was notified by the US Patent and Trademark
Office (USPTO) that its application for a core patent covering
the use of BIV201 to reduce ascites formation in ambulatory
patients has been allowed. A copy of the press releaseis attached
to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated into this Item8.01by reference.
Item 9.01.Financial Statements and Exhibits
|99.1||Press Release dated April 3, 2017|
About BioVie Inc. (OTCMKTS:BIVI)
BioVie, Inc., formerly NanoAntibiotics, Inc., is a development-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of drug therapies. The Company is focused on commercializing BIV201, which is used for the treatment of ascites due to liver cirrhosis. The Company’s therapy BIV201 is based on a drug that is approved in over 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites). The Company’s subsidiary is LAT Acquisition Corp. BioVie Inc. (OTCMKTS:BIVI) Recent Trading Information
BioVie Inc. (OTCMKTS:BIVI) closed its last trading session 00.000 at 0.300 with shares trading hands.